Evidence map›Paper›PMID 34545082›Full record

ArticleNature communications2021

Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid.

Yuhan Jiang, Yixiao Li, Cheng Liu, Lei Zhang, Danyu Lv, Yejing Weng, Zhongyi Cheng, Xiangmei Chen, Jun Zhan, Hongquan Zhang

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Linking cellular metabolism to chromatin modifications in plants.Journal of integrative plant biology · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Biochemistry and regulation of histone lysine L-lactylation.Nature reviews. Molecular cell biology · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Histone crotonylation in tumors (Review).Molecular and clinical oncology · 2025
    Review
  15. Review
  16. Article
  17. Cancer-AssociatedInternational journal of medical sciences · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Yuhan JiangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China.
Yixiao LiProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China.
Cheng LiuProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China.
Lei ZhangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China.
Danyu LvProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China.
Yejing WengJingjie PTM BioLab Co. Ltd., Hangzhou Economic and Technological Development Area, Hangzhou, PR China.
Zhongyi ChengJingjie PTM BioLab Co. Ltd., Hangzhou Economic and Technological Development Area, Hangzhou, PR China.
Xiangmei ChenDepartment of Microbiology & Infectious Disease Center, Peking University Health Science Center, Beijing, PR China.
Jun ZhanProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China.
Hongquan ZhangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, PKU International Cancer Institute, MOE Key Laboratory of Carcinogenesis and Translational Research and State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, PR China. Hongquan.Zhang@bjmu.edu.cn.ORCID 0000-0001-8193-0899
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoniazid (INH) is a first-line anti-tuberculosis drug used for nearly 70 years. However, the mechanism underlying the side effects of INH has remained elusive. Here, we report that INH and its metabolites induce a post-translational modification (PTM) of histones, lysine isonicotinylation (K

Indexed as

Histone CodeAcetylationAmino Acid SequenceAnimalsAntitubercular AgentsChromatinCoenzyme AHeLa CellsHep G2 CellsHistone Deacetylase 3Histone DeacetylasesHistonesHumansIsoniazidIsonicotinic AcidsLysineAntitubercular AgentsChromatinCoenzyme AHistone Deacetylase 3Histone DeacetylasesHistonesIsoniazidIsonicotinic AcidsLysinep300-CBP Transcription Factors

Identifiers

PMID34545082
PMCPMC8452692
OpenAlexW3200745244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.